OGC
GILD icon

Oak Grove Capital’s Gilead Sciences GILD Stock Holding History

Oak Grove Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$307K Sell
2,431
-369
-13% -$48.6K 0.01% 96
2026
Q1 		$390K Hold
2,800
– – 0.03% 78
2025
Q4 		$344K Hold
2,800
– – 0.04% 71
2025
Q3 		$311K Sell
2,800
-2,000
-42% -$227K 0.04% 67
2025
Q2 		$532K Sell
4,800
-7,200
-60% -$766K 0.09% 51
2025
Q1 		$1.34M Hold
12,000
– – 0.28% 42
2024
Q4 		$1.11M Hold
12,000
– – 0.17% 46
2024
Q3 		$1.01M Buy
12,000
+1,400
+13% +$107K 0.16% 42
2024
Q2 		$727K Buy
+10,600
New +$707K 0.13% 41
2022
Q2 		– Sell
-6,400
Closed -$380K – 73
2022
Q1 		$380K Sell
6,400
-4,450
-41% -$284K 0.08% 64
2021
Q4 		$788K Sell
10,850
-3,800
-26% -$262K 0.14% 62
2021
Q3 		$1.02M Sell
14,650
-25,531
-64% -$1.79M 0.22% 54
2021
Q2 		$2.77M Sell
40,181
-37,171
-48% -$2.48M 0.62% 38
2021
Q1 		$5M Sell
77,352
-1,600
-2% -$103K 1.4% 26
2020
Q4 		$4.6M Buy
78,952
+12,602
+19% +$760K 1.5% 27
2020
Q3 		$4.19M Buy
66,350
+30,171
+83% +$2.09M 1.98% 17
2020
Q2 		$2.78M Sell
36,179
-59,850
-62% -$4.59M 1.68% 16
2020
Q1 		$7.18M Sell
96,029
-102,496
-52% -$7.08M 4.64% 5
2019
Q4 		$12.9M Sell
198,525
-3,350
-2% -$218K 5.04% 3
2019
Q3 		$12.8M Buy
201,875
+96,100
+91% +$6.28M 5.55% 4
2019
Q2 		$7.15M Buy
105,775
+52,800
+100% +$3.47M 3.82% 6
2019
Q1 		$3.44M Buy
52,975
+22,350
+73% +$1.49M 2.17% 15
2018
Q4 		$1.92M Buy
30,625
+13,300
+77% +$930K 1.71% 16
2018
Q3 		$1.34M Sell
17,325
-500
-3% -$37.8K 1.15% 22
2018
Q2 		$1.26M Buy
17,825
+2,400
+16% +$169K 1.28% 20
2018
Q1 		$1.16M Sell
15,425
-13,050
-46% -$1.04M 1.28% 18
2017
Q4 		$2.04M Buy
+28,475
New +$2.16M 2.12% 14

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Oak Grove Capital's GILD Position: Q2 2026 in Review

Oak Grove Capital reduced its Gilead Sciences (GILD) stake by 13% in Q2 2026, selling an estimated $48.6K and leaving 2,431 shares worth $307K. The position accounts for 0.01% of the portfolio, ranked #96.

Oak Grove Capital first reported a position in GILD in Q4 2017 and has held it in 27 quarters since. The position peaked at $12.9M in Q4 2019. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Oak Grove Capital held 2,431 shares of Gilead Sciences worth $307K as of Q2 2026.
  • Oak Grove Capital sold 369 Gilead Sciences shares in Q2 2026, an estimated $48.6K.
  • Gilead Sciences made up 0.01% of Oak Grove Capital's portfolio in Q2 2026, its #96 holding.
  • Oak Grove Capital first reported a position in Gilead Sciences in Q4 2017 and has held it in 27 quarters since.
  • Oak Grove Capital's Gilead Sciences position peaked at $12.9M in Q4 2019.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Oak Grove Capital's 13F filing for Q2 2026, filed 13 Aug 2026.